PLAU and Alzheimer disease: Genes upregulated by EGCG treatment included the ribosomal protein Rpl17 and the urokinase-plasminogen activator gene Plau, which has been implicated in AD risk [30] and most notably the cell surface scavenger receptor CD36 which binds Aβ fibrils as part of a phagocytic response [31].